Piper Sandler lowered the firm’s price target on Dentsply Sirona (XRAY) to $16 from $20 and keeps a Neutral rating on the shares. Shares are cheap and investor confidence appears low, the firm notes. The difference between Dentsply and other inexpensive medtech stocks is that Piper believes the path to improving performance for peers is cleaner with fewer distractions. The firm will acknowledge that it may not take much for the stock to recapture a modicum of its multiple, but the combination of tariffs and challenges in key end markets leave it believing that rebound isn’t developing near-term.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- Dentsply Sirona price target lowered to $16 from $18 at Mizuho
- Dentsply Sirona downgraded to Equal Weight at Morgan Stanley
- Dentsply Sirona downgraded to Equal Weight from Overweight at Morgan Stanley
- Dentsply Sirona price target lowered to $16 from $19 at BofA
- Dentsply Sirona files automatic mixed securities shelf
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue